ITC1 Antibody

What is ICT01 and what molecular targets does it bind to?

ICT01 is a humanized monoclonal antibody that specifically targets butyrophilin 3A (BTN3A, also known as CD277). It binds to all three isoforms of BTN3A that are expressed on the surface of various cancer cells as well as immune cells. The antibody was specifically designed to activate γ9δ2 T cells, which are part of the innate immune system responsible for immunosurveillance against malignancy and infections .

Unlike conventional antibodies that block receptor function, ICT01 works through an activation mechanism that triggers downstream immune responses through BTN3A engagement. This unique mechanism distinguishes it from many other therapeutic antibodies in the immunotherapy landscape.

What cancer types show significant BTN3A expression that ICT01 could target?

Research has demonstrated that the three isoforms of BTN3A targeted by ICT01 are overexpressed on numerous solid tumors and hematological malignancies. Specific solid tumors with documented BTN3A overexpression include:

• Bladder cancer

• Colorectal cancer

• Melanoma

• Ovarian cancer

• Pancreatic cancer

• Lung cancer

Additionally, BTN3A is overexpressed in various hematologic cancers, particularly leukemia and lymphoma . This broad expression pattern across multiple cancer types suggests potential wide-ranging applications for ICT01 in cancer immunotherapy research.

Which immune cell populations express BTN3A and might be affected by ICT01?

BTN3A is expressed on the surface of multiple immune cell populations, including both innate and adaptive immune cells. Specifically, BTN3A expression has been documented on:

• Innate immune cells:

  • γδ T cells

  • Natural killer (NK) cells

• Adaptive immune cells:

  • T cells

  • B cells

This expression pattern suggests that ICT01 may have complex effects on the immune microenvironment, potentially engaging multiple immune cell populations simultaneously rather than targeting a single cell type.

How does ICT01 mechanistically activate γ9δ2 T cells in the tumor microenvironment?

ICT01 functions by engaging BTN3A on target cells, triggering a conformational change in the BTN3A protein that subsequently leads to activation of γ9δ2 T cells. When activated, these γ9δ2 T cells demonstrate several anti-tumor functions:

• Secretion of pro-inflammatory cytokines (including IFN-γ and TNF-α)

• Direct cytotoxicity against tumor cells

• Recruitment and activation of other immune cell populations

Clinical data from the EVICTION trial has shown that ICT01 administration leads to robust activation, migration, and tumor infiltration of not only γ9δ2 T cells but also CD8+ T cells and NK cells . This suggests a cascade effect where initial γ9δ2 T cell activation subsequently engages multiple arms of the immune system against the tumor.

What evidence supports ICT01's mechanism of action in human clinical studies?

The EVICTION clinical trial has provided substantial evidence supporting ICT01's mechanism of action. Key findings presented at major medical conferences (AACR, ESMO, and SITC) since 2021 have demonstrated:

• Safety of ICT01 administration in cancer patients

• Potent activation of γ9δ2 T cells following ICT01 treatment

• Enhanced migration of immune cells to tumor sites

• Increased tumor infiltration by γ9δ2 T cells, CD8 T cells, and NK cells

• Initial tumor responses in treated patients

Additionally, the detailed mechanistic studies published in Science Translational Medicine (October 2021) titled "Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell-mediated anti-tumor immune response" provide further molecular insights into how ICT01 engages its target and initiates immune activation .

How might ICT01 overcome resistance mechanisms observed with other immunotherapies?

ICT01 offers several potential advantages that may help overcome resistance to current immunotherapies:

• Novel target engagement: By activating γ9δ2 T cells, ICT01 engages an arm of the immune system distinct from those targeted by checkpoint inhibitors (which primarily focus on αβ T cells).

• MHC-independent recognition: γ9δ2 T cells can recognize stress ligands on tumor cells in an MHC-independent manner, potentially bypassing the downregulation of MHC that occurs as a resistance mechanism to conventional T cell therapies.

• Multifaceted immune activation: The ability of ICT01 to indirectly activate NK cells and CD8+ T cells suggests it may trigger a broader immune response than single-target approaches.

• Activity in "cold" tumors: Preliminary data suggests γ9δ2 T cell activation may help convert immunologically "cold" tumors (lacking T cell infiltration) to "hot" tumors by recruiting additional immune cells, potentially addressing a major limitation of current immunotherapies.

What are the optimal storage and handling conditions for ICT01 antibody in laboratory settings?

Based on standard practices for monoclonal antibodies used in research:

• Storage temperature: Store at -20°C to -70°C for long-term preservation (up to 12 months from receipt)

• Short-term storage: For periods up to 1 month, store at 2-8°C under sterile conditions after reconstitution

• Extended storage after reconstitution: For up to 6 months, store at -20°C to -70°C under sterile conditions

• Avoid freeze-thaw cycles: Use a manual defrost freezer and minimize repeated freeze-thaw cycles to maintain antibody integrity and function

These recommendations follow standard antibody handling protocols similar to those for other research-grade monoclonal antibodies used in laboratory settings.

What experimental methods are effective for validating ICT01's engagement with BTN3A?

Researchers studying ICT01 can employ several methods to validate target engagement:

• Flow cytometry: To confirm binding of ICT01 to BTN3A on target cells using fluorescently-labeled secondary antibodies

• Immunohistochemistry (IHC): For visualization of BTN3A expression in tissue samples and confirming ICT01 binding patterns

• Surface plasmon resonance (SPR): To determine binding kinetics and affinity of ICT01 to recombinant BTN3A

• Functional assays: Measuring γ9δ2 T cell activation (CD69 upregulation, cytokine secretion) following ICT01 treatment of BTN3A-expressing cells

• Competitive binding assays: Using labeled ICT01 and unlabeled competitors to map binding epitopes and confirm specificity

When developing new IHC protocols, researchers should follow standard validation approaches including optimization of antigen retrieval, antibody dilution, and incubation conditions to achieve optimal signal-to-noise ratios .

What controls should be included in experimental designs using ICT01?

For rigorous experimental design with ICT01, the following controls should be considered:

• Isotype control antibody: A matched isotype control antibody to detect non-specific binding and background signals

• BTN3A-negative cell lines: Cell lines lacking BTN3A expression to confirm specificity of ICT01 effects

• BTN3A knockdown/knockout models: Genetic manipulation of BTN3A expression to validate antibody specificity

• Blocking experiments: Pre-blocking BTN3A with competitive ligands to confirm mechanism

• Positive controls: Known BTN3A-overexpressing cell lines or tissues

• Functional readout controls: When assessing γ9δ2 T cell activation, include known activators (such as phosphoantigens) as positive controls

These controls help establish the specificity and functional relevance of observed effects, essential for publication-quality research.

How should researchers interpret variability in γ9δ2 T cell responses to ICT01 across different donor samples?

Variability in γ9δ2 T cell responses to ICT01 across different donors is a critical consideration for experimental design and data interpretation. Researchers should:

• Characterize baseline γ9δ2 T cell frequency: Donor-to-donor variation in circulating γ9δ2 T cell numbers can significantly impact response magnitude

• Assess BTN3A expression levels: Quantify BTN3A expression on target cells, as variation may affect ICT01 efficacy

• Consider γ9δ2 T cell differentiation status: Naive, effector, and memory γ9δ2 T cell subsets may respond differently to ICT01 stimulation

• Statistical approach: Use appropriate statistical methods for high-variability data:

  • Paired analyses when possible

  • Larger sample sizes to account for donor variability

  • Report individual donor responses alongside aggregated data

• Stratification analysis: Consider stratifying donors based on characteristics that might influence response (age, sex, disease status)

What technical factors can affect experimental outcomes when using ICT01 in laboratory settings?

Several technical factors can significantly impact ICT01 experimental outcomes:

Controlling these variables and reporting them transparently improves experimental reproducibility.

What combination strategies with ICT01 show promise in preclinical research?

Based on the mechanism of action of ICT01 and current trends in cancer immunotherapy, several combination approaches warrant investigation:

• Checkpoint inhibitor combinations: Combining ICT01 with anti-PD-1/PD-L1 antibodies may enhance T cell responses by simultaneously activating γ9δ2 T cells and removing inhibitory signals from conventional T cells

• Chemotherapy combinations: Certain chemotherapeutics induce immunogenic cell death, potentially enhancing BTN3A expression and/or releasing tumor antigens that could synergize with ICT01-mediated immune activation

• Radiation therapy combinations: Radiation can upregulate stress ligands recognized by γ9δ2 T cells and may enhance ICT01 efficacy

• Targeted therapy combinations: Combining ICT01 with targeted therapies that modulate specific oncogenic pathways could create synergistic anti-tumor effects

• Cytokine therapy combinations: IL-15 or IL-21 can enhance γ9δ2 T cell function and may potentiate ICT01 efficacy

• NK cell engagers: Given that ICT01 can indirectly activate NK cells, combining with NK cell-engaging therapies might potentiate anti-tumor responses

For each combination, researchers should carefully design studies that establish not only additive but potentially synergistic mechanisms of action.

What biomarkers might predict response to ICT01 therapy in research models?

Several potential biomarkers warrant investigation for predicting ICT01 response:

• BTN3A expression levels: Quantitative assessment of BTN3A expression in tumor samples using IHC or flow cytometry

• Baseline γ9δ2 T cell frequency and phenotype: Enumeration and characterization of circulating and tumor-infiltrating γ9δ2 T cells

• Genetic biomarkers: Genomic alterations associated with BTN3A expression or function

• Immune contexture analysis: Comprehensive profiling of the tumor immune microenvironment to identify patterns associated with response

• Peripheral immune monitoring: Changes in circulating immune cell populations and activation states following ICT01 treatment

• Serum cytokine profiling: Measurement of cytokines associated with γ9δ2 T cell activation

• Tumor mutational burden: Higher mutational burden may correlate with increased stress ligand expression recognized by γ9δ2 T cells

Development of robust biomarker panels will require correlation of these parameters with functional responses to ICT01 in preclinical models and eventually in clinical samples.